Biopartners GmbH and LG Life Sciences Ltd (LGLS) Present Positive Phase 3, Twenty-Four Months Efficacy and Safety Data for Sustained Release Recombinant Human Growth Hormone (LB03002) Given to Children with Growth Hormone Deficiency
Biopartners GmbH and LG Life Sciences Ltd (LGLS) today presented positive Phase 3 results of 24 months efficacy and safety in children with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth hormone (hGH), at the 50th annual meeting of the European Society for Paediatric Endocrinology (ESPE 2011) in Glasgow, Scotland.
A Phase 3 trial conducted globally, including Europe and the US, involving 167 paediatric patients with GHD demonstrated that LB03002, using LGLS’ proprietary delivery technology Biohydrix® , maintained expected growth rates for patients continuously treated for 24 months as well as in patients treated for 12 months who were switched from daily therapy. IGF-1 levels continued to increase toward the normal range in both groups during LB03002 treatment, a key marker of efficacy and safety in growth hormone therapy. LB03002 was well tolerated and demonstrated a sustained growth potential without excessive bone maturation.
Commenting on these new results Dr. Conrad Savoy, CEO of Biopartners GmbH said, “We are truly excited about the positive impact of this innovative once-a-week recombinant human growth hormone. These positive data further confirm previously presented positive data in children with GHD from a two year comparative trial versus daily growth hormone which was followed by a one year extension."
Dr. Hyi-Jeong Ji, VP of hGH Development at LGLS commented, “Based on this comprehensive set of data in GHD children together with 12 months of efficacy and safety in GHD adults, we believe this novel once-a-week hGH will offer a very attractive treatment modality to endocrinologists and their patients, leading to better adherence to long-term therapy, and ultimately, a more successful treatment outcome.”
LB03002 was originally developed by LGLS who granted Biopartners a license to further develop and market the product in Europe, Australia, New-Zealand and several other countries. LGLS retains rights in the rest of the world including North and South America, and most Asian countries including Korea, Japan, and China. An extension of this paediatric Phase 3 study is currently ongoing in India and Egypt.
About BioHydrix®
BioHydrix® is an LGLS proprietary sustained release (SR) technology with significant potential in the delivery of biologics. The unique hyaluronan microparticle matrix enables extended release of active substance.
About Biopartners
Established in 2000, Biopartners' aim is to be a leader in developing and commercializing innovative formulations and novel delivery systems of first-generation biopharmaceuticals for which there are substantial unmet medical/patients' needs.
Biopartners seeks to offer safe and efficacious biopharmaceutical therapies. Its product portfolio covers the fields of endocrinology, multiple sclerosis and virology.
With its head office located in Switzerland, and an affiliate located in Germany, Biopartners is building an international network through a series of collaborations and partnerships. For more information, please visit the company’s website at: www.biopartners.ch .
About LG Life Science
LG Life Sciences, Ltd. is the leading Korean pharmaceutical company based in Seoul, Korea, committed to promoting the health and well-being of patients. The company’s key therapeutic areas include metabolic and cardiovascular diseases as well as infectious and liver diseases. LGLS seeks to continue developing global brand products such as Factive® (gemifloxacin) and expanding its marketing presence across the globe. For more information, please visit the company’s website at: www.lgls.com .
Contact:
Biopartners GmbH
Dr Conrad Savoy
E-mail: Conrad@biopartners.ch
Tel:
+41 41 766 2080
LG Life Sciences, Ltd.
Junhyung Park
E-mail:
chunjae@lgls.com
Tel: +82 2
6924 3366
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 07:00:00 CEST | Press release
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1 Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3 This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4 Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy o
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 06:30:00 CEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 03:30:00 CEST | Press release
Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contr
DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Production Capacity by 15%18.6.2025 03:20:00 CEST | Press release
- To accommodate large-scale TVs and high-end model demands - Dai Nippon Printing Co., Ltd. (DNP) is pleased to announce the September operational launch of a coating device compatible with 2,500 mm-width high functional optical film at our Mihara Plant in Hiroshima Prefecture. The operational launch of the second wide coating device comes in response to market and consumer needs, and will boost production capacity by more than 15% on an area basis. With the increased capacity, DNP will accommodate the demand for high functional optical film for 65-inch large-screen TVs, with horizontal and vertical dimensions of 1,436.4 mm x 809.0 mm, which are expected to increase at a compound annual growth rate (CAGR) of approximately 6% between 2025 and 20301 on an area basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613720341/en/ Image of Mihara Plant [Features] Facilitates the efficient manufacture, or imposition, of high fun
Alipay Enables In-Store Payment Functionality in China for AR Glasses in Collaboration with Rokid to Build Immersive Commerce18.6.2025 02:27:00 CEST | Press release
Over 250,000 units of Rokid Glasses have already been ordered, integrated with Alipay’s digital payment technology for AR glasses.The integration of payments into AR glasses supports a future of seamless, intuitive commerce—enabling instant, gesture-based transactions, immersive product discovery, and new ways for businesses to engage customers. Rokid, a pioneer in augmented reality (AR), today launched Rokid Glasses, its latest AR device. In China, the product supports in-store payments facilitated by Alipay’s digital payment technology and multidimensional risk control solution for AR glasses, providing a seamless and secure payment experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617845457/en/ Rokid partners with Alipay to launch China’s first AR glasses with in-store payment capabilities. According to Rokid, the product will begin rolling out to users starting in June 2025, with over 250,000 units already or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom